Research Paper · Canine Parvovirus (CPV)
Development of a novel canine parvovirus vaccine capable of stimulating protective immunity in four-week-old puppies in the face of high maternal antibodies (Nobivac DP PLUS)
Why it matters: This is the challenge study behind Nobivac DP Plus, the CPV-2c vaccine recommended on the parvo clinical update page for closing the four-to-sixteen-week maternal-antibody vulnerability window.
Open access, CC BY 4.0
This page is part of the Dog Health Research Hub, a DOI-linked reference library for canine parvovirus and canine distemper research, curated by Annette Thompson, a medical technologist, not a veterinarian. Provided for clinical information only; treatment decisions belong with a qualified veterinarian who knows the individual patient.